Fed. Circ. Reverses Initial Panel To Find Gilenya IP Invalid
By Andrew Karpan (June 21, 2022, 11:07 PM EDT) -- The Federal Circuit held Tuesday that Novartis' patent covering its multibillion-dollar multiple sclerosis drug Gilenya isn't valid after all, reversing an earlier panel that found in favor of the Swiss drugmaking giant.
The split panel on Tuesday ruled that a Delaware federal court erred by rejecting an argument from Chinese pharmaceutical company HEC Pharm that Novartis' patent was invalid, finding that language in the patent failed to describe exactly how the drug it covered should be dosed. The decision reversed a split ruling by a Federal Circuit panel in January that had backed the lower court's decision.
Third Circuit Judge Kent Jordan...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!